avatar for Rebecca Blanchard

Rebecca Blanchard

CRISPR Therapeutics
Vice President
Cambridge, MA
Dr. Blanchard’s career in academia and industry has spanned basic, translational, and clinical research. She is currently responsible for Clinical Biomarkers and Exploratory Research, Assay Development and Pharmacology/Toxicology at CRISPR Therapeutics. After receiving her Ph.D. in Pharmaceutical Chemistry at the University of Utah, Rebecca completed postdoctoral studies at the Mayo Clinic (pharmacogenomics, clinical pharmacology). Rebecca spent 13 years at Merck where she help leadership positions in Clinical Pharmacology, Oncology and Clinical Pharmacogenomics. Rebecca has had a strong external scientific presence including ASCPT Board of Directors, ICH E18 Working Group, National Academy of Sciences, and Industry Pharmacogenomics WG.